Reviva Pharmaceuticals Holdings Inc.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $5
- Today's High:
- $5.46
- Open Price:
- $5.02
- 52W Low:
- $1.56
- 52W High:
- $9.25
- Prev. Close:
- $4.98
- Volume:
- 229294
Company Statistics
- Market Cap.:
- $93.09 million
- Book Value:
- 0.072
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -115.99%
- Return on Equity TTM:
- -347.02%
Company Profile
Reviva Pharmaceuticals Holdings Inc. had its IPO on 2018-10-18 under the ticker symbol RVPH.
The company operates in the Healthcare sector and Biotechnology industry. Reviva Pharmaceuticals Holdings Inc. has a staff strength of 10 employees.
Stock update
Shares of Reviva Pharmaceuticals Holdings Inc. opened at $5.02 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $5 - $5.46, and closed at $5.39.
This is a +8.23% increase from the previous day's closing price.
A total volume of 229,294 shares were traded at the close of the day’s session.
In the last one week, shares of Reviva Pharmaceuticals Holdings Inc. have increased by +28.95%.
Reviva Pharmaceuticals Holdings Inc.'s Key Ratios
Reviva Pharmaceuticals Holdings Inc. has a market cap of $93.09 million, indicating a price to book ratio of 3.5947 and a price to sales ratio of 0.
In the last 12-months Reviva Pharmaceuticals Holdings Inc.’s revenue was $0 with a gross profit of $0 and an EBITDA of $-10103922. The EBITDA ratio measures Reviva Pharmaceuticals Holdings Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Reviva Pharmaceuticals Holdings Inc.’s operating margin was 0% while its return on assets stood at -115.99% with a return of equity of -347.02%.
In Q2, Reviva Pharmaceuticals Holdings Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Reviva Pharmaceuticals Holdings Inc.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.41 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Reviva Pharmaceuticals Holdings Inc.’s profitability.
Reviva Pharmaceuticals Holdings Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -5.2436. Its price to sales ratio in the trailing 12-months stood at 0.
Reviva Pharmaceuticals Holdings Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $11.84 million
- Total Liabilities
- $9.21 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Reviva Pharmaceuticals Holdings Inc. ended 2024 with $11.84 million in total assets and $0 in total liabilities. Its intangible assets were valued at $11.84 million while shareholder equity stood at $1.62 million.
Reviva Pharmaceuticals Holdings Inc. ended 2024 with $0 in deferred long-term liabilities, $9.21 million in other current liabilities, 2265.00 in common stock, $-110216666.00 in retained earnings and $0 in goodwill. Its cash balance stood at $11.15 million and cash and short-term investments were $11.15 million. The company’s total short-term debt was $222,500 while long-term debt stood at $0.
Reviva Pharmaceuticals Holdings Inc.’s total current assets stands at $11.84 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $2.65 million and inventory worth $0.
In 2024, Reviva Pharmaceuticals Holdings Inc.'s operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Reviva Pharmaceuticals Holdings Inc. paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $5.39
- 52-Week High
- $9.25
- 52-Week Low
- $1.56
- Analyst Target Price
- $15.4
Reviva Pharmaceuticals Holdings Inc. stock is currently trading at $5.39 per share. It touched a 52-week high of $9.25 and a 52-week low of $9.25. Analysts tracking the stock have a 12-month average target price of $15.4.
Its 50-day moving average was $4.54 and 200-day moving average was $4.94 The short ratio stood at 9.44 indicating a short percent outstanding of 0%.
Around 2185.8% of the company’s stock are held by insiders while 607.5% are held by institutions.
Frequently Asked Questions About Reviva Pharmaceuticals Holdings Inc.
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company’s lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention”deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer’s disease, Parkinson’s disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.